Bristol-Myers Squibb Foundation's SECURE THE FUTURE(R) Works to Reduce the Impact of HIV and Tuberculosis Epidemic in Africa

Community-Based Programs Confront Challenges Associated With Dual Epidemic -

VIENNA, July 20, 2010 - Bristol-Myers Squibb Company (NYSE: BMY) and the Bristol-Myers Squibb
Foundation announced at the XVIII International AIDS Conference in Vienna the
community-based projects that it is currently supporting in resource-poor
regions across Africa to help combat the challenge of HIV and tuberculosis
co-infection.

In 2008, 1.3 million people died from tuberculosis globally(1), and
500,000 people died of HIV-associated tuberculosis.(2) As such, tuberculosis
is the biggest killer of people living with HIV in Africa and a major cause
of death elsewhere.(2)

This initiative is an element of SECURE THE FUTURE(R), a philanthropic
program that provides care and support for communities affected by HIV/AIDS
in Africa. In its eleventh year, SECURE THE FUTURE(R) is one of the largest
public-private corporate philanthropic commitments of its kind to fight the
HIV/AIDS pandemic in Africa. In 2008, SECURE THE FUTURE(R) entered a new
phase as a technical assistance and skills transfer program, which aims to
replicate SECURE THE FUTURE(R)'s lessons, experiences and successful models,
address a strategic challenge of operational multi-sectoral collaborations in
HIV by harnessing community resources and capacity.

"Over the past decade, projects supported by SECURE THE FUTURE(R) have
accumulated substantial experience in delivering innovative community-based
interventions to support the HIV-positive population in resource-deprived
areas of Africa. Now we are deploying lessons learned from these
interventions to tackle tuberculosis as part of our mandate to fight HIV,"
said John Damonti, President, Bristol-Myers Squibb Foundation. "Our Technical
Assistance Program remains robust and responsive with partners in 21 African
countries. It leverages the successes, experiences and learnings from SECURE
THE FUTURE(R) past grant recipients to provide training and technical
assistance and empower communities to improve the effectiveness and
sustainability of multi-sectoral, community-based HIV/AIDS programs."

Recently, Bristol-Myers Squibb Foundation has provided backing for new
innovative community-based projects focusing on working closely with local
communities to improve the diagnosis, support, education and treatment for
HIV-positive members who are also infected with tuberculosis.

Four projects have received SECURE THE FUTURE(R) technical assistance
grants to aid communities in sub-Saharan Africa, KwaZulu-Natal, Eastern Cape
Provinces and Luthando. In addition, Bristol-Myers Squibb Foundation has
partnered with Baylor International Pediatric AIDS Initiative (BIPAI) to
develop the network of children's centres in Africa, supported by SECURE THE
FUTURE(R). All this builds on the experience gained with community-based
approaches pioneered by previous SECURE THE FUTURE(R) programs for the
broader population of people affected by HIV/AIDS over the last decade.

Projects Supported by SECURE THE FUTURE(R) Presented at AIDS 2010

Among the projects supported by SECURE THE FUTURE(R) presented at AIDS
2010 is the Bambisanani Project Community Tuberculosis Program in South
Africa, which was initiated to create ownership and full participation of the
communities in the management of tuberculosis at a household level by
bringing health and laboratory services directly into the community. This has
generated strong local support and helped build trust between care workers
and family members. Since 2005, Bambisanani screened more than 35,000 people
for tuberculosis, 18,000 of whom were referred to initiate treatment, about
5,500 in 2009 alone and close to 16,000 people who have completed
treatment.(5)

Ms. Nombuyiselo Tshumane, Director of Bambisanani, said: "In 2009, we
screened approximately 10,000 people, collecting 20,000 sputa specimens in
hard-to-reach villages. This was a three-fold increase from 2005, when we
first started. The difference we make is that we unlock the potential of
communities and create a suitable environment for care and support in
partnership with government and community leaders."

Bambisanani is a flagship project that is part of Vumbulula (Unearth) TB
programme, which is a comprehensive community outreach, education and
prevention programme focusing on three sites that have high burden of
tuberculosis in KwaZulu-Natal and Eastern Cape, South Africa. It is a
one-year pilot study initiated in June 2010 that involves mass community and
home based tuberculosis screening and referrals for HIV testing counseling,
drawing on projects by SECURE THE FUTURE(R)'s long-term partner, Bambisanani
and some key learnings from Mpilonhle. While the two experienced sites will
be learning for each other, they will simultaneously provide technical
assistance to a new site, which will be chosen to introduce the intervention
and to assess replicability in similar settings.(7)

Mpilonhle is a non-governmental organization (NGO) running a successful
initiative in KwaZulu-Natal, in South Africa, the HAST + Ca Program. This is
a health education program on HIV/AIDS, sexually transmitted infections,
tuberculosis and cancer involving household visits by nurses who treat
tuberculosis patients, door to door health education, distribution of
educational materials and condoms and formation of support groups. The HAST +
Ca Program also traces those patients who default on their tuberculosis and
HIV treatments. A new element to the program involves community screening to
help increase diagnosis of people with early-stage tuberculosis.(6)

Beyond HAST + Ca Program, another initiative showcased at AIDS 2010 is
run by Luthando Psychiatric HIV Clinic. It enhances access to tuberculosis
and HIV services in communities with high burden of tuberculosis by utilising
intensive case identification and providing antiretroviral treatment to
mentally ill HIV patients, who are at increased risk of contracting and
transmitting HIV and tuberculosis. Tuberculosis identification, diagnosis and
adherence to treatment amongst this vulnerable group poses a significant
challenge to clinicians.(8)

Other abstracts accepted to AIDS 2010 included the development of
pharmacist-based HIV/AIDS services in Southern Africa,(9) and a novel
spreadsheet program for pharmacy-based antiretroviral drug monitoring.(10)

Baylor International Pediatric AIDS Initiative Network (BIPAI) is yet
another SECURE THE FUTURE(R) project showcased at AIDS 2010. BIPAI consists
of a network of seven Children's Centres of Excellence in sub-Saharan Africa
and Eastern Europe for the care and treatment of children and their families
infected and affected by HIV/AIDS. More than 68,000 patients are under its
care. Given that tuberculosis is a major cause of death among HIV-infected
children older than 12 months,(3) BIPAI's personnel have been trained in the
symptomatic screening of tuberculosis and BIPAI predominantly follows the WHO
guidelines for treatment of tuberculosis in HIV-infected children. BIPAI has
also launched several research studies examining tuberculosis incidence,
effectiveness of anti-tuberculosis therapy in relation to HIV treatment and
identifying those patients at risk for tuberculosis.

A recent analysis presented at AIDS 2010 evaluated the mortality rate on
HAART and its effectiveness among 2,171 children treated at the Children's
Centres of Excellence (COE) in southern Africa. The study found that
annualized mortality decreased progressively with increasing duration of
therapy from 10.1% in February 2008 to 4.7% in September 2009.(4)

"TB infection is a deadly risk for people living with HIV in the more
resource-deprived areas of Africa, especially so for children," said Dr.
Richard Sebastian Wanless, V.P. of Research and Program Evaluation for Baylor
International Pediatric AIDS Initiative and Medical Director of the Baylor
Black Sea Foundation in Romania. "We are extremely grateful to the SECURE THE
FUTURE(R) program for supporting our initiatives addressing this challenge."

About SECURE THE FUTURE(R)

SECURE THE FUTURE(R) is Bristol-Myers Squibb's flagship philanthropic
program that provides care and support for communities affected by HIV/AIDS
in Africa. Over the past 11 years, the program has funded more than US$150
million in programs in 21 African countries, with special emphasis on
community treatment support programs, care for children and building
infrastructure.

SECURE THE FUTURE(R) has evolved and remained agile over the years in
order to play as relevant a role as possible in the global response to
HIV/AIDS. In 2008, SECURE THE FUTURE(R) entered a new phase as a technical
assistance and skills transfer program.

The Technical Assistance Program leverages the successes, experiences and
learnings from SECURE THE FUTURE(R) and empowers communities to harness
resources and capacity to improve the effectiveness and sustainability of
multi-sectoral, community-based HIV/AIDS programs.

SECURE THE FUTURE(R) is a registered trademark of Bristol-Myers Squibb
Company.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help patients
prevail over serious diseases.

    REFERENCES

     1) WHO. Estimated tuberculosis incidence, prevalence and
        mortality, 2008. Available at
        www.who.int/mediacentre/factsheets/fs104/en/. Accessed 30 June
        2010
     2) WHO. 2009 Update Tuberculosis Facts. 2009. Available at
        www.who.int/tb/challenges/hiv/factsheet_hivtb_2009update.pdf.
        Accessed 25 June 2010.
     3) Cotton, MF et al. Int J Tuberc Lung Dis 8(5): 675-682
     4) Wanless R. S. et al. Mortality and ART efficacy outcomes in
        children < 12 years on ART in Lesotho, Swaizland and Malawi. Abstract
        accepted to AIDS 2010.
     5) Tshamane N. "Bambisanani Project: tackling HIV and TB in OR
        Tambo District, South Africa since 2003" draft abstract submitted for
        satellite presentation to IAC 2010
     6) HAST+ Cancer Program, abstract submitted to AIDS 2010.
     7) PROJECT VUMBULULA: Expanded Community Based tuberculosis support
        Concept Note, DATED 18.5.10
      Greg J. Enhancing access to tuberculosis and HIV services
        amongst mentally ill patients in high burden tuberculosis communities
        through intensive case identification, abstract submitted to AIDS
        2010.
     9) "Addressing the critical needs for Pharmacist-based HIV/AIDS
        services in Southern Africa," abstract accepted to AIDS 2010.
    10) "Efficacy of a Novel Spreadsheet Program for Pharmacy-based
        Antiretroviral (ARV) Monitoring in Southern Africa," abstract
        accepted to AIDS 2010.

Europe: Annie Simond, +33-6-08-95-67-62, or Joanna Ritter, +33-6-14-58-08-96; or USA : Sonia Choi, +1-609-213-60-15